A Study of DZD2269 in Healthy Adult Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteers
In brief
This is a research study in healthy participants. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing. This study will also investigate pharmacokinetics of DZD2269; renal excretion of DZD2269 will also be evaluated. The study will also measure biomarkers such as pCREB in the blood.
Key facts
- Study ID
- NCT04932005
- Run by
- Dizal Pharmaceuticals
- People needed
- 72
- Starts
- 2021-06-29
- Expected to finish
- 2022-04-12
- Last updated by the study team
- 2022-07-01
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Frontage Clinical Service 200 Meadowlands Parkway — Secaucus, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.